Definitive Radiotherapie und Radiochemotherapie der Vulva und Vagina

Dimopoulos, J.; Fidarova, Elena; Pötter, Richard

doi:10.1007/s00761-008-1541-8

Cited by 3 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The response rates with the platinum-containing scheme appear to be slightly higher at first sight [72], and theseareparticularlyduetodosagedifferencesintheradiotherapy. The studies show wide differences in dosage, fractionation,andfieldselection.Ingeneral,thedrugsneedtobe selectedwithaneyeonthesideeffectprofile,andthenephrotoxicity of platinum-containing chemotherapeutic agents, particularly in older patients with several concomitant diseases,oftenrepresentsalimitingfactor.…”

Section: Conflict Of Interestmentioning

confidence: 99%

“…For radiotherapy, 50 Gy in the preoperative situation and at least 60 Gy for definitivetreatmentarerecommended [72]. Thesideeffectprofileisquitedifferentfromtheprimary operation.…”

Section: Vulvar Carcinomamentioning

confidence: 99%

“…The classictreatmentisstillsurgery [72].Primaryorpostoperative radiotherapyisonlycarriedoutinindividualcases.Theseinclude patients with locally advanced vulvar carcinoma (Fedcombinationtherapywithcisplatin(50mg/m 2 ,d1,q28d)and MMC (6 mg/m 2 , d1, q28d) [62]. Clinical benefit was seen in 69% (complete remission 15%, partial remission 27%, stabledisease27%).Themedianprogression-freeperiodwas 5.0 months (95% confidence interval (CI), 6.2-15.2 months) and the median survival was 11.2 months (95% CI, 6.5-18.4 months).…”

Section: Vulvar Carcinomamentioning

confidence: 99%

See 2 more Smart Citations

Mitomycin C in Patients with Gynecological Malignancies

et al. 2010

View full text Add to dashboard Cite

Mitomycin C (MMC) is an effective cytostatic agent used in the treatment of patients with gynecological malignancies and breast carcinoma. This review presents and discusses the current treatment options with MMC in patients with breast, cervical, and vulvar carcinomas, as well as rarer gynecological malignancies. New combinations and developments are also presented and their potential clinical relevance is examined. Consequently, also for the next years a MMC-containing chemotherapy continues to be a relevant part of an individualized therapy despite numerous innovative new drugs, especially for the salvage therapy of metastatic breast cancer and the simultaneous radiochemotherapy of other gynecological malignancies.

show abstract

Section: Conflict Of Interestmentioning

confidence: 99%

“…For radiotherapy, 50 Gy in the preoperative situation and at least 60 Gy for definitivetreatmentarerecommended [72]. Thesideeffectprofileisquitedifferentfromtheprimary operation.…”

Section: Vulvar Carcinomamentioning

confidence: 99%